Figure 3

Kaplan-Meier plots of disease-specific survival and metastasis-free survival of high-risk upper urinary tract urothelial carcinomas (pT3 or pT4 or with nodal metastasis) with or without cisplastin-based adjuvant chemotherapy. Kaplan-Meier plots show high-risk patients who received cisplastin-based adjuvant chemotherapy conferred significant prognostic impacts on disease-specific survival (DSS) (A). The DSS of patients with HuR high expression in tumor cells was significantly improved by adjuvant chemotherapy (C). The MeFS was also improved in those with HuR high expression in tumor cells if adjuvant chemotherapy was given but was not statistically significant (B and D). Adjuvant chemotherapy did not change the DSS and MeFS in the patients with low HuR expression in tumor cells (E and F).